POSTER SESSION A • Monday, May 19, 4:45-7:15 p.m.

(In board number order)

Development

A1, PR06 The ampullary adenocarcinoma, its molecular characterization and differentiation from the pancreatic ductal adenocarcinoma, duodenal adenocarcinoma, and cholangiocarcinoma. Marie-Claude Gingras.


A3, PR01 Downregulation of PTF1A is a crucial and rate-limiting step in pancreatic cancer initiation. Nathan Michael Krah.


A5 Probing tumor phenotypes by transposon mediated stable RNAi in a new genetically engineered pancreatic cancer mouse model. Lars Zender.


A7 Ductal organoids as models of pancreatic cancer. Chang-il Hwang.

A8 Activation of Wnt/β-catenin in acinar cells accelerates Kras-induced PDAC, while activation of Wnt signaling pathways in stroma induces mucinous cystic neoplasm. Makoto Sano.

A9, PR02 DCLK1-positive cells represent a unique pancreatic cellular lineage in a subset of intraductal papillary mucinous neoplasms. Gloria H. Su.

A10 In search of Kras resistance genes: Whole transcriptome analysis identifies critical pathways mediating resistance and sensitivity to oncogenic Kras. Jennifer M. Bailey.


A12 Establishing in vitro and in vivo models of pancreatic ductal adenocarcinoma (PDA) utilizing both acinar and ductal lineages. Jesse Handler.


A14 SOX9 regulates ERBB signaling in pancreatic cancer development. Patrick Jacquemin.


A17 The role of post-translational activation of MYC in pancreatic cancer development and progression. Rosalie C. Sears.

A18 Syndecan-1 is required for oncogenic Kras-driven PDAC tumorigenesis and maintenance. Wantong Yao.

A19 Prrx1 transcription factor variants alter induced pluripotent stem cell induction efficiency and pancreatic terminal differentiation. Gregory P. Botta.

A20 Molecular dissection of pancreatic cancer invasion and metastasis. Shin-Heng Chiou.

A21 Stromal-derived TGFβ facilitates pancreatic cancer development via repression of T-cell mediated cytotoxicity. Brian DeCant.

A22 CXCL12-CXCR4 chemotactic pathway modulates metastasis and perineural invasion in pancreatic cancer. Qingyong Ma.


A24 CD133 initiates tumors, induces epithelial-mesenchymal transition, and increases metastasis in pancreatic cancer. Alice Nomura.


A26 ZIP4 confer resistance to apoptosis induced by zinc deficiency in pancreatic cancer. Xiaobo Cui.

A27 Redefining the role of Notch in acinar to ductal metaplasia. Christopher J. Halbrook.


A29 Involvement of glucocorticoid signaling in acinar-to-ductal metaplasia and oncogenic Kras-mediated transformation in pancreas. Pei-Yu Lin.

A30 Reconstituting pancreatic cancer precursor lesions ex vivo. Bryan Lo.

A31 Posttranslational modifications of Chmp1A and their effects on human pancreatic cancer cells. Maiyon Park.

A32 Characterization of pancreatic ductal adenocarcinoma patients using whole-transcriptome sequencing and copy number analysis by SNPs array techniques. Mariacristina Di Marco.


A34 Regulation of pancreatic cells by isomiRs. Eric R. Londin.

A35 Insulin and hypoxia-inducible factor-1 cooperate to increase the viability of pancreatic cancer cells. Yue Chen.
A36 Role of histone H3 lysine 27 tri-methylation in the regulation of microRNA expression in pancreatic cancer. Yangchao Chen.

A37 MSI is not an important feature in early onset pancreatic carcinoma. Monica A.J. Van Zanten.

A38 Adiponectin receptor agonists cause inhibition of pancreatic cancer proliferation. Michael Nathan VanSaun.

A39 The activation of β1-integrin by type I collagen coupling with the Hedgehog pathway promotes the epithelial-mesenchymal transition in pancreatic cancer cells. Qingyong Ma.

A40 The role of Yap in pancreatic ductal adenocarcinoma. Chunling Yi.

A41 The interaction between BIRC6 and PIM kinases and their role in gemcitabine chemosensitivity in pancreatic cancer cells. Antonio T. Baines.

Inflammation/Stroma


A43 Lysyl oxidases are poor therapeutic targets in pancreatic cancer. Mario A. Shields.


A45 Understanding the roles of extracellular matrix proteins in pancreatic ductal adenocarcinoma progression and metastasis. Chenxi Tian.

A46 The Ets-transcription factor Etv1 induces epithelial-mesenchymal transition (EMT) and invasion as well as expands the stromal compartment in vivo. Koushik K. Das.


A48, PR11 CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice. Yaqing Zhang.


A50 p120 catenin regulates PanIN epithelial cell delamination in preinvasive pancreatic cancer. Audrey M. Hendley.

A51 Novel Hedgehog co-receptors in pancreatic cancer. Esha Mathew.


A53 Chemotherapy treated pancreatic cancer tumor-associated fibroblasts are protumorigenic. Paul A. Toste.


A56 The role of Pentraxin 3 (PTX3) in pancreatic ductal adenocarcinoma. Jennifer Watt.

A57 GPCRs as potential therapeutic targets in pancreatic cancer-associated fibroblasts. Shu Zhou.

A58 Macrophage migration inhibitory factor (MIF) and miR-301b interactively enhance disease aggressiveness by targeting NR3C2 in human pancreatic cancer. S. Perwez Hussain.


A60 The hMENA Splicing Program: An important regulator of TGFβ1-driven EMT and invasiveness in pancreatic cancer. Paola Nisticò.

A61 Exploring the PDAC-subtype-associated microenvironment in PDX models and patients. Elisa Espinet.

Heterogeneity in Tumor Progression


A63, PR05 p120 catenin-mediated epithelial-to-mesenchymal plasticity determines the metastatic potential of pancreatic ductal adenocarcinoma. Maximilian Reichert.

A64 Haploinsufficiency of TGFBR2 in a genetically engineered mouse model recapitulates the oligometastatic phenotype of human pancreatic cancer. Yi Zhong.

A65 Pancreatic cancer stem cell function is regulated by HNF1A. Ethan V. Abel.


A68 Hypoxia-induced CHK1 repression may enhance the mutator phenotype of pancreatic cancer cells. Salvador Naranjo-Suarez.


A70 The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. Asma Begum.

A71 Post-transcriptional regulation of the proto-oncogene PIM1 by the mRNA stability factor HuR: Implications for pancreatic cancer therapeutic response and cell survival. Fernando F. Blanco.
A72 Protein isoforms of the RON tyrosine kinase receptor transform human pancreatic ductal epithelial cells and induce acinar to ductal metaplasia. Jeffery M. Chakedis.


A75 Investigating the role of the chromatin-associated protein Hmga2 in PDAC metastasis. Barbara M. Gruener.

A76 Loss of GLI1 accelerates pancreatic cancer progression in the KPC mouse model. Lisa D. Mills.

A77 Investigating the role of ADAM10 in pancreatic tumor differentiation. Louise V. Peverley.

A78 Profiling of miRNA interactions in pancreatic adenocarcinoma by Argonaute CLIP-seq suggests a highly dynamic repertoire of targets. Kevin Quann.


A80 The role of PHLPP in pancreatic cancer. Alena Smith.

A81 A microRNA signature identified for chemoresistance and mesenchymal phenotype is also found in advanced pancreatic cancer. James W. Freeman.


A83 Nuclear morphometry differentiates chronic pancreatitis, IPMN, and pancreatic carcinoma. Evan S. Glazer.

A85 Collagen triple helix repeat containing-1 enhances the aggressiveness of pancreatic tumor by increased cancer cell motility and adhesiveness. Leem Sun-Hee.

**New Therapies**


A87, PR13 Pancreatic tumor stem cells resistant to inhibition of oncogenic signaling are dependent on mitochondrial function. Andrea Viale.


A89 Targeting the MYC activation and degradation pathway for the treatment of pancreatic cancer. Amy S. Farrell.


A91 IKBKE signaling in pancreatic tumorigenesis. Mihir Rajurkar.
A92 Murine clinical trials program. Shelley M. Thorsen.


A94 Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Avnish Kapoor.


A97 Control of PDAC tumor progression by RNA interference targeting indoleamine 2,3-dioxygenase using Salmonella as a delivery vehicle facilitated by PEGPH20. Edwin R. Manuel.

A98 IL-1 receptor inhibitor inhibits NF-kB activity and enhance gemcitabine effect to reduce pancreatic cancer growth. Zhuonan Zhuang.

A99 Discovery of new therapeutic targets in MEK inhibitor resistant PDAC. Jaymes Beech.

A100 Role of HER3 ligand-independent activation in EGFR resistance in pancreatic cancer. Donald J. Buchsbaum.


A102 Combination treatment with hypoxia-activated prodrug TH-302 and radiation reduce pancreatic tumor initiating cells and tumor growth in patient-derived xenografts. Ines Lohse.

A103 Intracellular immunotherapy of disseminated pancreatic cancer activates potent IFNγ and CD8+ T cell dependent anti-tumor responses. Kiah L. Sanders.


A106 BRCA mutation sensitizes pancreatic tumors to treatment with cisplatin. Ines Lohse.

A107 c-Met overexpression as an independent prognostic biomarker and therapeutic target in patients with poor prognostic pancreatic adenocarcinoma following surgical resection. Cindy Neuzillet.


A110 Adjuvant gemcitabine/nab-paclitaxel and chemoradiotherapy in high-risk pancreatic adenocarcinoma. Susan Williams.
A111 PI3K/AKT/mTOR and Sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth in NOD/SCID/IL2γ null mice. Rakesh K. Srivastava.

A112 Eradication of cancer stem-like cells in PDAC. Thiruvengadam Arumugam.

A113 Immunomodulatory properties of bromodomain inhibitors in pancreatic cancer cells. Ana S. Leal.


A115 The CD95 ligand inhibitor APG 101 reduces tumor recurrence and metastasis in an adjuvant orthotopic mouse model of pancreatic cancer as well as primary tumor load in a palliative setting. Holger Kalthoff.


A118 An open label pilot study of NovoTTF therapy concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma (NCT01971281). Uri Weinberg.

A119 Assessment and optimization of electroporation assisted tumoral nanoparticle uptake in a pancreatic adenocarcinoma nude mouse model. Derek Lamont West.

A120 PGRMC1 protects pancreatic cancer cells from apoptosis by gemcitabine. John R. Hornick.

A121 Suppression of orthotopic pancreatic cancer growth by sulforaphane is associated with activation of FOXO transcription factors. Sharmila Shankar.

A122 Case review for multi-targeted epigenetic therapy (MTET) and its rationale in an integrative approach. Mohammad Nezami.

A123 Diallyl trisulfide induces G2/M phase cell cycle arrest and upregulates cyclin-dependent kinase inhibitor p21Waf1/Cip1 in pancreatic cancer cells. Silvia Stan.
POSTER SESSION B • Tuesday, May 20, 12:30-3:00 p.m.

(In board number order)

Inflammation/Stroma


B2, PR03 Mesenchymal stem cells in pancreatic cancer possess unique properties in promoting tumor growth and metastasis. Meghna Waghray.

B3 Role of Hif1α in pancreatic tumorigenesis. Kyoung Eun Lee.


B5 Assessing and removing biophysical barriers to treatment. Kathleen E. DelGiorno.

B6 Impact of intratumoral microenvironment and epithelial cells crosstalk in pancreatic carcinogenesis. Richard Tomasini.

B7 Diet-induced obesity leads to differential inflammation of adipose tissue depots and cytokine profile modifications in the KrasG12D mouse model. Kathleen Hertzer.

B8 The role of periostin in pancreatic carcinogenesis and metastatic spread. Simone Hausmann.

B9 Targeting macrophages to degrade fibrosis in pancreatic ductal adenocarcinoma. Kristen B. Long.

B10 Function and therapeutic implications of p53 in the stroma of pancreatic cancer. Maya Ridinger.


B12 Circulating stroma-related molecules as potential biomarkers for pancreatic ductal adenocarcinoma. Dorina Belotti.

B13 Oncogenic K-ras in pancreatic acinar cells induces expression of chemoattractants that cause macrophage infiltration to expedite formation and progression of precancerous lesions. Geou-Yarh Liou.


B16 Contributions of Ras and EZH2 in acinar to ductal metaplasia and ductal carcinoma in transgenic mouse pancreas. Marxa L. Figueiredo.
B17 Tumor-associated stellate cells promote an invasive phenotype of pancreatic cancer cells. Emelie Karnevi.


B19 Redox factor 1 (Ref-1) signaling in the interaction between pancreatic tumor cells and cancer-associated fibroblasts. Melissa L. Fishel.

**Diagnostics**

B20 Development and validation of diagnostic biomarker model for detection of early stage pancreatic cancer. Ayumu Taguchi.

B21 Detection of somatic mutations in fine needle aspirates of pancreatic cancer with next-generation sequencing. Vicente Valero.

B22 Circulating tumor cells as an adjunctive biomarker for diagnosis and staging in pancreatic cancer patients. Jacob S. Ankeny.

B23 Plasma basigin as an early detection biomarker for pancreatic adenocarcinoma. Samaa Kamal.


B25 Development of 5B1, an anti-CA19.9 monoclonal antibody, as a near-infrared fluorescent probe for intraoperative imaging of pancreatic cancer. Jacob L. Houghton.

B26, PR07 Transcriptome meta-analysis identifies new 5-gene classifier for early detection of pancreatic cancer. Towia Aron Libermann.

B27 Development of a targeted imaging agent for the detection of PDAC and PDAC metastases. Stephanie A. Thomas.


B29 Adjusting CA19-9 for biliary obstruction in pancreatic cancer. Lindsay A. Bliss.

B30 High expression of PIGR is an independent favorable prognostic factor in pancreatic and periampullary adenocarcinoma. Richard Fristedt.


B32 Special AT-rich sequence-binding protein 1 (SATB1) is an independent prognostic marker of poor prognosis in operated pancreatic and pancreatobiliary type adenocarcinomas. Jacob Elebro.

B33 Classification of pancreatic cysts in a minority population through cytokine profiling of cyst fluid fine-needle aspirate. Laura Martello.
B34 Diagnostics of pancreatic duct hypertension by the serotonin-stimulated magnetic resonance cholangiopancreatography. Alexey Kashintsev.

Metabolism

B36, PR09 Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression. Aram Hezel.

B37, PR08 Pulling out all the stops: Exploiting macropinocytosis inhibition for the treatment of pancreatic cancer. Cosimo Commisso.

B38 Transcriptional control of the autophagy-lysosome system drives amino acid metabolism in pancreatic cancer. Rushika M. Perera.

B39 Targeting HIF-1 alpha and downstream metabolic flux in pyrimidine biosynthetic pathway diminishes gemcitabine resistance in pancreatic cancer. Pankaj Kumar Singh.

B40 Oncogenic Kras induces histone acetylation in pancreatic ductal adenocarcinoma. Alessandro Carrer.

B41 Mitochondrial metabolism, the Achilles heel of pancreatic cancer stem cells. Christopher Heeschen.

B42 Metabolic changes, associated with loss of the tumor suppressor LKB1, promote tumorigenesis. Filippos Kottakis.


B44 The histone deacetylase SIRT6 regulates metabolism in pancreatic ductal adenocarcinoma. Sita Kugel.


B46 Low mitochondrial activity of CD133+ population enables evasion of apoptosis leading to increased chemoresistance in tumor initiating cells. Sulagna Banerjee.

B47 Modulating the NQO1-dependent "kiss of death" mechanism of action of NQO1 bioactivatable drugs. Boothman A. David.

B48 Pancreatic cancer cells exhibit heterogeneous glucose and glutamine metabolic dependencies. Kirsten L. Bryant.

B49 Alpha-enolase knockdown reprograms metabolism and points out targetable pathways to counteract PDA growth. Sammy Ferri-Borgogno.

B50 Abrogating cholesterol esterification suppresses pancreatic cancer growth and metastasis mediated by caveolin-1. Junjie Li.

B51 Effects of dietary fatty acids on pancreatic cancer. Hongyi Liu.
B52 The role of extracellular superoxide dismutase activity in pancreatic cancer biology and therapy. James J. Mezhir.

B53 Effects of metformin and ATP-competitive inhibitor of mTOR on targeted-metabolomic profile in HPAF-II pancreatic cancer cell lines. Ghada A. Soliman.

B54 Mechanism of action of antiausterity agents. Satoshi Owada.

B55 Chemokine biased agonists regulate pancreatic cancer migration and metastasis through bioenergetic signaling. Ishan Roy.

B56 Inactivation of LKB1-AMPK pathway is mediated by inflammation in pancreatic cancer. Sita Aggarwal.


**Immunology**

B58, PR10 Re-engineering immunity to treat pancreas cancer. Ingunn M. Stromnes.

B59 Transnuclear mice as models of the immune response to pancreatic cancer. Stephanie K. Dougan.

B60 Role of inflammatory monocyte mobilization in metastatic pancreatic cancer. Roheena Z. Panni.

B61 CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. David DeNardo.

B62 The role of B regulatory cells in pancreatic cancer. Yuliya Pylayeva-Gupta.

B63 Improving CAR T cell function by reversing the immunosuppressive tumor environment of pancreatic cancer. Somala Mohammed.

B64 A Lys-Ala-Leu-Ala (KALA) repeated peptide modification in DNA nanoparticles of DOPE/CHEMS, follows GPCR-mediated transgene expression in dendritic cell. Sharif Mohammad Shaheen.

**New Therapies**

B65, PR12 Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine cancers. Geoffrey Wayne Krampitz.

B66 The nonmutated PI3Kα is a master signaling enzyme for pancreatic cancerogenesis. Julie Guillermet-Guibert.

B68 Therapeutic effect of tamoxifen on mucinous cystic neoplasms (MCN). Libing Feng.

B69 Preclinical evaluation of a PARP inhibitor in mice representing genetically different subtypes of pancreatic cancer. Barbara Orelli.

B70 Developing a new and potent anti-K-RAS strategy by inhibiting SIAH E3 ligase, the most downstream “gatekeeper” in the oncogenic K-RAS signal pathway, to block well-established pancreatic tumor growth. Amy H. Tang.


B72 Developing drug combinations to co-target pancreatic cancer and its supporting stroma. Elisabete Florencio Carapuça.

B73 Adrenergic signaling promotes pancreatic tumor initiation and progression. Bernhard W. Renz.

B74 Minimally invasive ablative therapy for mucinous cystic neoplasms (MCN) in a genetically engineered mouse model. Carlos Cuevas.


B76 Targeting Mcl-1 for radiosensitization of pancreatic cancers. Meredith A. Morgan.

B77 Vitamin D suppresses pancreatic cancer growth through inhibition of autocrine Wnt/β-catenin signaling. Michael Dawson Arensman.

B78 Warfarin blocks Gas6-mediated Axl activation required for pancreatic tumor plasticity and metastasis. Rolf A. Brekken.

B79 Carboxylesterase 2 as a potential determinant of response to irinotecan in pancreatic cancer. Michela Capello.

B80 Pancreatic cancer cells resistant to JQ1 inhibitor demonstrate cell-cell and cell-matrix adhesion defects driven by ZEB1 and activation of Hedgehog signaling. Lawrence Knab.

B81 Targeted inhibition of Vav1, a driver of pancreatic cancer invasion and metastasis. Gina L. Razidlo.

B82 Chemoprevention of pancreatic cancer by targeting Kras mutations for apoptosis. Oksana Zagorodna.

B83 Cannabinoids as an adjuvant therapy for pancreatic cancer. Andy D. Hospodor.


B87 Cell lines generated from PDAC transgenic mice reveal integrin αvβ6 modifies the invasive phenotype of pancreatic cancer. Claire S. Reader.


B91 Identification of human UGT isoforms responsible for glucuronidation of Arctigenin. Takanori Kawashima.

B92 Targeting the STAT3/NF-κB signaling axis through combination treatment with NexrutineR and gemcitabine for pancreatic cancer. Amanda Rae Muñoz.


B94 Polyamine starvation as a potential therapy for pancreatic cancer. Meenu Madan.

B95 Is ethanol required for cyst ablation in patients with premalignant type pancreatic cysts? Setareh Sharzehi.

Clinical Science Trials

B96 Nonviral gene therapy for pancreatic cancer, from preclinical models to phase II clinical trial. Pierre Cordelier.

B97 A phase II trial of low-dose multiagent chemotherapy with gemcitabine, taxotere, xeloda, and cisplatin (GTX-C) in subjects with metastatic pancreatic cancer. Luis A. Diaz.

B98 Final results of a randomized phase Ib study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having at least two prior therapies. Vincent J. Picozzi.


B101 Rapid immunohistochemical analysis of pancreatic cancer cytology from endoscopic ultrasound-guided fine needle aspirates. Susan Tsai.
B102 A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation. Robert H. Vonderheide.

B104 Pancreatic satellite cells derived galectin-1 increase the progression and less survival of pancreatic ductal adenocarcinoma. Dong Tang.

B105 Significance of BRCA mutation for the patients with pancreatic cancer. Alexey Kashintsev.

Other


B107 BET proteins are key mediators of pancreatic cancer cell growth and its tumor microenvironment. Andrew S. Liss.

B108 Dclk1 labels reserved progenitor cells involved in pancreatic regeneration. Yoshihiro Takemoto.


B111 Functional analysis of the chr13q22.1 pancreatic cancer risk locus suggests allele-specific effects on DIS3 expression with prognostic implications. Jason W. Hoskins.

B112 Transcriptome analysis in pancreatic cancer reveals a tumor suppressor function for HNF1A. Jason W. Hoskins.

B113 Prevalence of germline BRCA and mismatch repair (MMR) gene mutations in pancreatic cancer. Iris Selander.

B114 c-Rel is a critical mediator of NF-κB dependent TRAIL resistance of pancreatic cancer cells. Alexander Arlt.

B115 PD0332991 induces epithelial to mesenchymal transition in pancreatic cancer. I. E. Imasuen.


B119 Triptolide abrogates expression of the Met and epidermal growth factor receptors in pancreatic cancer. Veena Sangwan.

B120 Wnt expression and the association with autophagy protein in pancreatic cancer. Myung Ah Lee.
B121 Surgical resection after silencing of ZIP4 significantly improves survival of pancreatic cancer through inhibiting cachexia and p38 MAPK pathway. Jingxuan Yang.

B122 Hypoxia-inducible factor (HIF)-1α Directly Activates the Leptin Receptor (Ob-R) in pancreatic cancer cells. He Ren.

B123 The value of tissue phenotype as a predictor in advanced pancreatic ductal adenocarcinoma (PDAC) receiving either Gemcitabine (G) or FOLFIRINOX (F). Lauren Peirce Carcas.